Vericel Corporation (NASDAQ:VCEL) is listed as one of the Best Small-Cap Growth Stocks to Buy Right Now. Leerink Partners raised the firm’s price target on VCEL from $50 to $57 with a Buy rating, despite slightly missing revenue estimates in Q2. The company’s strategic plan and training efforts aim to drive growth through 2026.

Analyst Mike Kratky finds VCEL’s current valuation below historic averages. Management expects stable expenses for the rest of the year, making the risk/reward situation attractive. Vericel Corporation focuses on developing advanced therapies for sports medicine and severe burn care, positioning it as a potential investment opportunity.

While Vericel Corporation (NASDAQ:VCEL) presents investment potential, some believe there are AI stocks with greater upside and lower risk. For those interested in an undervalued AI stock benefiting from current trends, a free report on the best short-term AI stock is available. Explore other stock opportunities with reports on 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Read more at Yahoo Finance: Leerink Partners Raises the PT Vericel (VCEL), Maintains a Buy Rating